RESUMO
JAA-F11 is a highly specific mouse monoclonal to the Thomsen-Friedenreich Antigen (TF-Ag) which is an alpha-O-linked disaccharide antigen on the surface of ~80% of human carcinomas, including breast, lung, colon, bladder, ovarian, and prostate cancers, and is cryptic on normal cells. JAA-F11 has potential, when humanized, for cancer immunotherapy for multiple cancer types. Humanization of JAA-F11, was performed utilizing complementarity determining regions grafting on a homology framework. The objective herein is to test the specificity, affinity and biology efficacy of the humanized JAA-F11 (hJAA-F11). Using a 609 target glycan array, 2 hJAA-F11 constructs were shown to have excellent chemical specificity, binding only to TF-Ag alpha-linked structures and not to TF-Ag beta-linked structures. The relative affinity of these hJAA-F11 constructs for TF-Ag was improved over the mouse antibody, while T20 scoring predicted low clinical immunogenicity. The hJAA-F11 constructs produced antibody-dependent cellular cytotoxicity in breast and lung tumor lines shown to express TF-Ag by flow cytometry. Internalization of hJAA-F11 into cancer cells was also shown using a surface binding ELISA and confirmed by immunofluorescence microscopy. Both the naked hJAA-F11 and a maytansine-conjugated antibody (hJAA-F11-DM1) suppressed in vivo tumor progression in a human breast cancer xenograft model in SCID mice. Together, our results support the conclusion that the humanized antibody to the TF-Ag has potential as an adjunct therapy, either directly or as part of an antibody drug conjugate, to treat breast cancer, including triple negative breast cancer which currently has no targeted therapy, as well as lung cancer.
RESUMO
Modulating the host response, including the accumulation of oxidized lipid species, is important for improving tissue engineered vascular graft (TEVG) viability. Accumulation of oxidized lipids promotes smooth muscle cell (SMC) hyper-proliferation and inhibits endothelial cell migration, which can lead to several of the current challenges for small-diameter TEVGs. Generating biomaterials that reduce lipid oxidation is important for graft survival and this assessment can provide a reliable correlation to clinical situations. In this study, we determined the collagen to poly(ε-caprolactone) (PCL) ratio required to limit the production of pro-inflammatory species, while maintaining the required mechanical strength for the graft. Electrospun conduits were prepared from 0%, 10%, and 25% blends of collagen/PCL (w/w) and implanted in the rat peritoneal cavity for four weeks. The results showed that adding collagen to the PCL conduits reduced the accumulation of oxidized lipid species within the implanted conduits. In addition, the ratio of collagen had a significant impact on the recruited cell phenotype and construct mechanics. All conduits exhibited greater than 44% yield strain and sufficient tensile strength post-implantation. In conclusion, these results demonstrate that incorporating collagen into synthetic electrospun scaffolds, both 10% and 25% blend conditions, appears to limit the pro-inflammatory characteristics after in vivo implantation.